Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Apr
27
Today In Oncology
Long-Term Immunotherapy for Alveolar Soft Part Sarcoma
AMA Data Show Nearly 50 Percent of Surveyed Oncologists Reported Burnout in 2025
Unique Phase I NSCLC Trial Sites Decreasing in United States
Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo